The evolving definition of carcinogenic human papillomavirus

被引:32
作者
Castle P.E. [1 ]
机构
[1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, MSC 7234, Bethesda, MD 20892-7234
基金
美国国家卫生研究院;
关键词
Cervical Cancer; Cervical Cancer Screening; Screen Positive; Public Health Advocate; Cervical Precancer;
D O I
10.1186/1750-9378-4-7
中图分类号
学科分类号
摘要
Thirteen human papillomavirus (HPV) genotypes have been judged to be carcinogenic or probably carcinogenic, and the cause of virtually all cervical cancer worldwide. Other HPV genotypes could possibly be involved. Although the inclusion of possibly carcinogenic HPV genotypes may hurt test specificity, it may indirectly increase the reassurance following a negative HPV test (i.e. the negative predictive value of an HPV test for cervical precancer and cancer). The future of cervical cancer screening in low-resource setting, however, may include once-in-a-lifetime, low-cost and rapid HPV testing. However, the tradeoff of more false positives for greater reassurance may not be acceptable if the local infrastructure cannot manage the screen positives. Now is the time for the community of scientists, doctors, and public health advocates to use the data presented at the 100th International Agency for Research on Cancer monograph meeting to rationally decide the target HPV genotypes for the next generation of HPV tests for use in high-resource and low-resource settings. The implications of including possibly HPV genotypes on HPV test performance, also for guidance on the use of these tests for cervical cancer prevention programs, are discussed.
引用
收藏
相关论文
共 28 条
[1]  
Human Papillomaviruses. [90], IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, (2007)
[2]  
Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Carcinogenicity of human papillomaviruses, Lancet Oncol, 6, (2005)
[3]  
Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El G.F., A review of human carcinogens Part B: Biological agents, Lancet Oncol, 10, pp. 321-322, (2009)
[4]  
Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Cecilia R.A., The carcinogenicity of human papillomavirus types reflects viral evolution, Virology, 20, 337, pp. 76-84, (2005)
[5]  
Schiffman M., Khan M.J., Solomon D., Herrero R., Wacholder S., Hildesheim A., A study of the impact of adding HPV types to cervical cancer screening and triage tests, J Natl Cancer Inst, 97, pp. 147-150, (2005)
[6]  
Hiller T., Poppelreuther S., Stubenrauch F., Iftner T., Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification, Cancer Epidemiol Biomarkers Prev, 15, pp. 1262-1267, (2006)
[7]  
Muench P., Hiller T., Probst S., Florea A.M., Stubenrauch F., Iftner T., Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes, Virology, (2009)
[8]  
De Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis, Lancet Infect Dis, 7, pp. 453-459, (2007)
[9]  
Castle P.E., Stoler M.H., Solomon D., Schiffman M., The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses:An ALTS Report, Am J Clin Pathol, 127, pp. 805-815, (2007)
[10]  
Castle P.E., Schiffman M., Wheeler C.M., Solomon D., Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia-Grade 2, Obstet Gynecol, 113, pp. 18-25, (2009)